

1: Mazzaferro V, **Battiston C**, Sposito C.

Extended Oncologic Indications in Liver Transplantation: PRO (with caution).

Liver Transpl. 2018 Jan;24(1):98-103

2: Berenato R, Morano F, Pietrantonio F, Cotsoglou C, Caporale M, Infante G, Pellegrinelli A, Alessi A, **Battiston C**, Coppa J, Padovano B, Mennitto A, Niger M, Fucà G, Lazzati S, Greco G, Delconte G, de Braud F, Mazzaferro V, Di Bartolomeo M.

Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions.

Oncology. 2017 Sep 8. doi: 10.1159/000479154. [Epub ahead of print]

3: Sposito C, Di Sandro S, Brunero F, Buscemi V, **Battiston C**, Lauterio A, Bongini M, De Carlis L, Mazzaferro V.

Development of a prognostic scoring system for resectable hepatocellular carcinoma.

World J Gastroenterol. 2016 Sep 28;22(36):8194-202.

4: Sposito C, **Battiston C**, Facciorusso A, Mazzola M, Muscarà C, Scotti M, Romito R, Mariani L, Mazzaferro V.

Propensity score analysis of outcomes following laparoscopic or open liver resection for hepatocellular carcinoma

Br J Surg. 2016 Jun;103(7):871-80.

5: Villanueva A, Portela A, Sayols S, **Battiston C**, Hoshida Y, Méndez-González J, Imbeaud S, Letouzé E, Hernandez-Gea V, Cornella H, Pinyol R, Solé M, Fuster J, Zucman-Rossi J, Mazzaferro V, Esteller M, Llovet JM; HEPTROMIC Consortium.

DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma.

Hepatology. 2015 Jun;61(6):1945-56.

6: Villanueva A, Hoshida Y, **Battiston C**, Tovar V, Sia D, Alsinet C, Cornella H, Liberzon A, Kobayashi M, Kumada H, Thung SN, Bruix J, Newell P, April C, Fan JB, Roayaie S, Mazzaferro V, Schwartz ME, Llovet JM. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

Gastroenterology. 2011 May;140(5):1501-12.e2.

7: Vartanian JP, Henry M, Marchio A, Suspène R, Aynaud MM, Guétard D, Cervantes-Gonzalez M, **Battiston C**, Mazzaferro V, Pineau P, Dejean A, Wain-Hobson S. Massive APOBEC3 editing of hepatitis B viral DNA in cirrhosis.

PLoS Pathog. 2010 May 27;6(5):e1000928.

8: Pineau P, Volinia S, McJunkin K, Marchio A, **Battiston C**, Terris B, Mazzaferro V, Lowe SW, Croce CM, Dejean A.

miR-221 overexpression contributes to liver tumorigenesis.

Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):264-9.

9: Porretti L, Cattaneo A, Colombo F, Lopa R, Rossi G, Mazzaferro V, **Battiston C**, Svegliati-Baroni G, Bertolini F, Rebulli P, Prati D.

Simultaneous characterization of progenitor cell compartments in adult human liver.

Cytometry A. 2010 Jan;77(1):31-40.

10: Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi GL, Adam R, Neuhaus P, Salizzoni M, Bruix J, Forner A, De Carlis L, Cillo U, Burroughs AK, Troisi R, Rossi M, Gerunda GE, Lerut J, Belghiti J, Boin I, Gugenheim J, Rochling F, Van Hoek B, Majno P; Metroticket Investigator Study Group.

Collaborators :Graziadei I, Vogel W, Lerut J, Lucidi V, de Hemptinne B, Troisi R, Boin I, Leopardi L, Cotsoglou C, Gugenheim J, Iannelli A, Staccini A, Adam R, Belghiti J, Neuhaus P, Koenigsrainer A, Steurer W, Cautero N, Risaliti A, Lupo L, Colledan M, De Giorgio M, Fagioli S, Grazi GL, Pinna AD, Ravaioli M, **Battiston C**, Coppa J, Regalia E, Romito R, De Carlis L, Giacomoni A, Mangoni J, Maggi U, Rossi G, Gerunda GE, Masetti M, Montalti R, Calise F, Cuomo O, Scuderi E, Brida A, Cillo U, Vitale A, Tisone G, Berloco P, Rossi M, Paraluppi G, Patrono D, Salizzoni M, Adani GL, Baccarani U, Lorenzin D, Van Hoek B, Zieniewicz K, Ribeiro V, Bruix J, Forner A, Llovet JM, Soderdahl G, Giostra E, Mentha G, Morel P, Burroughs AK, Marelli L, Patch D, Muiesan P, Heaton N, Roayaie S, Schwartz M, Rossaro L, Khatri V, Rochling F, Hsieh CB.

Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria:

a retrospective, exploratory analysis.
Lancet Oncol. 2009 Jan;10(1):35-43.

11: Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, Tovar V, Roayaie S, Minguez B, Sole M, **Battiston C**, Van Laarhoven S, Fiel MI, Di Feo A, Hoshida Y, Yea S, Toffanin S, Ramos A, Martignetti JA, Mazzaferro V, Bruix J, Waxman S, Schwartz M, Meyerson M, Friedman SL, Llovet JM.
Pivotal role of mTOR signaling in hepatocellular carcinoma.
Gastroenterology. 2008 Dec;135(6):1972-1983.

12: Morosi C, Civelli E, **Battiston C**, Schiavo M, Mazzaferro V, Severini A, Marchianò A.
CT holangiography: assessment of feasibility and diagnostic reliability.
Eur J Radiol. 2009 Oct;72(1):114-7.

13: Pineau P, Marchio A, **Battiston C**, Cordina E, Russo A, Terris B, Qin LX, Turlin B, Tang ZY, Mazzaferro V, Dejean A.
Chromosome instability in human hepatocellular carcinoma depends on p53 status and aflatoxin exposure.
Mutat Res. 2008 May 31;653(1-2):6-13.

14: Llovet JM, Chen Y, Wurmbach E, Roayaie S, Fiel MI, Schwartz M, Thung SN, Khitrov G, Zhang W, Villanueva A, **Battiston C**, Mazzaferro V, Bruix J, Waxman S, Friedman SL.
A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis.
Gastroenterology. 2006 Dec;131(6):1758-67.

15: Mazzaferro V, **Battiston C**, Perrone S, Pulvirenti A, Regalia E, Romito R, Sarli D, Schiavo M, Garbagnati F, Marchianò A, Spreafico C, Camerini T, Mariani L, Miceli R, Andreola S.
Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study.
Ann Surg. 2004 Nov;240(5):900-9